Uncategorized

At the 2024 Annual Meeting of the American Society for Radiation Oncology (ASTRO), the second interim analysis of the Phase III NRG-LU005 trial revealed the importance of timing when combining immunotherapy with chemoradiotherapy for limited-stage small cell lung cancer (SCLC). The findings showed no significant survival benefits for patients who received atezolizumab concurrently with chemoradiotherapy (cCRT) compared to those who received cCRT alone.

From October 18 to 19, 2024, the CACA Gastric Cancer Integration Conference was held in Wuhan, bringing together multidisciplinary experts from both domestic and international fields to focus on the frontiers, standards, and progress in gastric cancer diagnosis and treatment. During the conference, Oncology Frontier had the opportunity to interview the conference chairman, Dr. Han Liang, from Tianjin Medical University Cancer Institute and Hospital. Dr. Liang shared insights into his journey to becoming a surgeon, the professional qualities required of surgeons, and the future trends in surgical oncology. His extensive clinical experience and unique perspectives revealed the challenges and honors behind the career of a surgeon, as well as the limitless possibilities of medical advancements.

The 27th Annual National Clinical Oncology Conference and 2024 CSCO Academic Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. Multiple forums on lung cancer were held during the conference, summarizing the latest advances in lung cancer research globally. During the event, Oncology Frontier invited Dr. Changli Wang from Tianjin Medical University Cancer Institute and Hospital to interpret the main findings of the AK112-205 study and share insights into treatment strategies for resectable non-small cell lung cancer (NSCLC).

Excited to share this insightful talk with Dr. Liangyou Gu on tackling clear cell renal cell carcinoma with innovative approaches like neoadjuvant toripalimab. The future of kidney cancer treatment is evolving, and these advancements are offering real hope for better outcomes. Watch the video for key highlights!

In a groundbreaking discussion, Professor Nicolaus Kroger delves into the evolving landscape of allogeneic stem cell transplantation for myelofibrosis. Learn how post-transplant monitoring and strategic donor T cell activity enhancements…

At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100% response rate by two months, offering new hope to patients dealing with this life-threatening complication. As HLH has a high mortality rate, with most patients unable to receive adequate malignancy treatment due to complications, this study opens new doors for future integration with chemotherapy.

The Phase 3 Non-Small Cell Lung Cancer (NSCLC) Treatment ASCO Guidelines has recently been updated, with the revisions based on the results of the Phase 3 LAURA trial. The findings were presented at the 2024 ASCO Annual Meeting and published simultaneously in the New England Journal of Medicine [1, 2]. The new guidelines include a recommendation to use the EGFR-TKI osimertinib in patients with unresectable Stage III NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations after definitive chemoradiotherapy (CRT).